From Seattle Genetics Maps Out a Future With Antibody Drugs That Are “Empowered”:

claysiegall

claysiegall—

Clay Siegall is CEO of Seattle Genetics

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
Sept. 15 – Challenges of Implementing Innovation in Drug Discovery & Development
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery

From Our Editors · Podcast
Xcelerating Life Sciences San Francisco: The Highlights Podcast
The AI, Big Data, and R&D Boom

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Xconomy on Demand

We offer a number of ways to subscribe for free!